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Background-—The purpose of this study was to investigate the association between kidney function and arterial calciﬁcation in
major vascular beds and to establish whether arterial calciﬁcation mediates the relation between kidney function measures and
cardiovascular disease (CVD) incidence.
Methods and Results-—In 2241 participants from the Rotterdam Study (mean age 69 years, 52% female), kidney function was
assessed using the estimated glomerular ﬁltration rate and urine albumin-to-creatinine ratio. All participants underwent
noncontrast computed tomography to quantify the amount of arterial calciﬁcation in the coronary arteries, aortic arch, extracranial,
and intracranial internal carotid arteries. We used linear regression models, adjusted for age, sex, and cardiovascular risk factors,
to evaluate the association between kidney function and arterial calciﬁcation volume in the 4 vessel beds. Incidence rate of CVD
was calculated in 3 groups of participants based on their kidney function and presence of arterial calciﬁcation. We conducted
mediation analysis to evaluate whether arterial calciﬁcation mediates this association. We found that in age- and sex-adjusted
models, lower estimated glomerular ﬁltration rate and higher albumin-to-creatinine ratio were associated with larger calciﬁcation
volumes in all 4 vascular beds. Adjusting for cardiovascular risk factors attenuated the effect estimates. CVD incidence was higher
in participants with estimated glomerular ﬁltration rate <60 mL/min per 1.73 m2 and presence of arterial calciﬁcation compared
with individuals with estimated glomerular ﬁltration rate >60 and no calciﬁcation. After adjusting for cardiovascular risk factors,
arterial calciﬁcation did not mediate the association between kidney function measures and CVD incidence.
Conclusions-—The association of impaired kidney function and larger volumes of arterial calciﬁcation is partly explained by
cardiovascular risk factors. Arterial calciﬁcation does not mediate the association between kidney function and CVD beyond
cardiovascular risk factors. ( J Am Heart Assoc. 2019;8:e010930. DOI: 10.1161/JAHA.118.010930.)
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Impaired kidney function is accompanied by a higher risk ofcardiovascular events, such as myocardial infarctions and
stroke.1 One of the potential factors that can explain this
excess risk is arterial calciﬁcation,2 which seems to be more
prevalent in arteries of patients with chronic kidney disease
compared with healthy individuals.2,3
Arterial calciﬁcation is one of the strongest risk factors for
cardiovascular events and mortality.4 The calciﬁcation burden
differs considerably across different vessel beds and carries
differential predictive value for various manifestations of
cardiovascular events.5–8 Hence, it is important to understand
whether the association of impaired kidney function with
various forms of cardiovascular disease is through arterial
calciﬁcation in the relevant (or adjunct) vessels.6–9
In a large studyof community-dwellingmiddle-agedandelderly
people, we investigated the association between kidney function
and arterial calciﬁcation in 4 major vessel beds, including
coronary artery, aortic arch, and extracranial and intracranial
carotid artery calciﬁcation. We also studied the incidence of
cardiovascular disease in subgroupsof participantsbasedon their
kidney function level and calciﬁcation burden. Finally, we
conducted a mediation analysis to evaluate whether arterial
calciﬁcation mediates the association between impaired kidney
function and higher incidence of cardiovascular disease.
Methods
Study Population
The present study is embedded within the Rotterdam Study, a
prospective population-based study among individuals
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45 years and older living in Ommoord, a district of Rotterdam.
Between 2003 and 2006, all participants who visited the
research center were invited to undergo nonenhanced
multidetector computed tomography. In total, 2524 individ-
uals were scanned (response rate 78%). Among them, 2241
participants had serum creatinine measurements, 2195
serum cystatin C, and 1767 urinary albumin-to-creatinine
ratio.10 The Rotterdam Study has been approved by the
Medical Ethics Committee of the Erasmus MC (registration
number MEC 02.1015) and by the Dutch Ministry of Health,
Welfare and Sport (Population Screening Act WBO, license
number 1071272-159521-PG). The Rotterdam Study has
been entered into the Netherlands National Trial Register
(NTR; www.trialregister.nl) and into the World Health Organi-
zation International Clinical Trials Registry Platform (ICTRP;
www.who.int/ictrp/network/primary/en/) under shared cat-
alogue number NTR6831.10 All participants provided written
informed consent to participate in the study and to have their
information obtained from treating physicians. Requests to
access the data set from qualiﬁed researchers trained in
human subject conﬁdentiality protocols may be sent to
Department of Epidemiology, Erasmus MC University Medical
Center at f.vanrooij@erasmusmc.nl.
Assessment of Kidney Function Markers
Serum creatinine was measured with an enzymatic assay
method and standardized to isotope–dilution mass
spectrometry–traceable measurements.11 Serum cystatin C
was measured with a particle-enhanced immunonephelometric
assay.12 Estimated glomerular ﬁltration rate (eGFR) was
calculated for creatinine (eGFRcr) and cystatin C (eGFRcys)
on the basis of the Chronic Kidney Disease Epidemiology
Collaboration equation.13 Participants collected the ﬁrst
morning urine before arriving at the research center. Urine
albumin and creatinine were determined by a turbidimetric
method and measured by a Hitachi MODULAR P Analyzer
(Roche/Hitachi Diagnostics, Mannheim, Germany). Albumin-
to-creatinine ratio (milligrams per gram) was estimated by
dividing albumin by creatinine. We used log-transformed values
to obtain values per doubling of the albumin-to-creatinine ratio.
Before transformation, we added 1 to the values to account for
those who did not have albuminuria. On average, there was a 6-
and 5-year difference between the time of computed tomog-
raphy (CT) scans and eGFR and albumin-to-creatinine ratio
measurements, respectively. Hence, all analyses were adjusted
for the time interval between kidney functionmeasurement and
the time of the CT scans.
Assessment of Arterial Calciﬁcation
Noncontrast CT images were obtained using 16-slice (n=785)
or 64-slice (n=1739) multidetector CT scanners (Somatom
Sensation 16 or 64; Siemens, Forchheim, Germany). The
acquisition-protocol has been described in detail before.5–7 In
short, using a cardiac scan and a scan that reached from the
aortic arch to the intracranial vasculature (1 cm above the
sella turcica), we scanned the following vessels: coronary
arteries, aortic arch, extracranial carotid arteries, and
intracranial carotid arteries. We visualized and quantiﬁed the
amount of arterial calciﬁcation in these vessel beds. Coronary
artery calciﬁcation, aortic arch calciﬁcation, and extracranial
carotid artery calciﬁcation were quantiﬁed using commercially
available software (Syngo CalciumScoring; Siemens). Intracra-
nial carotid artery calciﬁcation was evaluated using a
semiautomatic scoring method that is described in detail
elsewhere (Figure 1).5 All calciﬁcation volumes are expressed
in cubic millimeters. Because calciﬁcation scores were not
normally distributed, we used natural log-transformed values
after adding 1 mm3 to the nontransformed values to account
for zero values. To correct for the size of the vessels and be
able to compare the effect estimates, we used standardized
values of log-transformed calciﬁcation scores.
Other Measurements
All covariables were assessed at the time of kidney function
measurements.10 Body mass index was calculated by dividing
participants’ weight in kilograms by the square of one’s height
in meters. Blood pressure was measured twice in a single visit
Clinical Perspective
What Is New?
• Impaired kidney function, assessed through estimated
glomerular ﬁltration rate for cystatin C and albumin-to-
creatinine ratio, is associated with higher volumes of
calciﬁcation in the coronary arteries, the aortic arch, and
the extra- and intracranial internal carotid arteries, but this
association is partly explained by the presence of traditional
cardiovascular risk factors.
• There was no evidence for a mediating role for arterial
calciﬁcation in the association between kidney function and
cardiovascular events beyond traditional cardiovascular risk
factors.
What Are the Clinical Implications?
• In the general population with mild-to-moderate kidney
impairment, a substantial portion of the association
between worse kidney function and arterial calciﬁcation is
explained by cardiovascular risk factors.
• Hence, these ﬁndings emphasize the need for novel
investigations into other mechanisms underlying the
increased risk of cardiovascular events in these individuals.
DOI: 10.1161/JAHA.118.010930 Journal of the American Heart Association 2
Kidney Function and Arterial Calciﬁcation Sedaghat et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on December 12, 2019
and the average of 2 measurements was used in the analyses.
Information on antihypertensive medication use was based on
home interview. Serum total and high-density lipoprotein
cholesterol levels were measured using an automated enzy-
matic method. Diabetes mellitus was ascertained using
general practitioners’ records (including laboratory glucose
measurements), hospital discharge letters, and serum glucose
measurements from the Rotterdam Study visits, which take
place approximately every 4 years. Information on smoking
was gathered using questionnaires.
Incidence of Cardiovascular Events
Cardiovascular events included fatal or nonfatal acute
myocardial infarction, coronary artery bypass grafting, percu-
taneous coronary intervention, and stroke. Information on
incident cases was obtained from general practitioners and
from letters and discharge reports of medical specialists.
Follow-up data until January 1, 2012 were used (median
follow-up=5.5 years). All participants with a history of
cardiovascular events at time of CT scanning were excluded
from the analyses involving incidence of cardiovascular
events.
Statistical Analysis
Associations between kidney function markers and arterial
calciﬁcation in the 4 vessel beds were evaluated using linear
regression models. Betas and 95% CIs for difference in arterial
calciﬁcation volume were estimated per SD decrease of eGFR
measures and doubling of albumin-to-creatinine ratio. We
performed analyses in 2 models. In the ﬁrst model, analyses
were adjusted for age, sex, and cohort. In the second model,
we additionally adjusted for cardiovascular risk factors
including body mass index, hypertension, diabetes mellitus,
smoking, total cholesterol, and high-density lipoprotein
cholesterol. To investigate a possible nonlinear association
between kidney function markers and arterial calciﬁcation, we
Figure 1. Visual representations of the vascular beds under study. AAC indicates aortic arch calciﬁcation; CAC, coronary artery calciﬁcation;
ECAC, extracranial carotid artery calciﬁcation; ICAC, intracranial carotid artery calciﬁcation.
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applied ordinary least squares linear regression models with
restricted cubic splines with 3 knots at the 10th, 50th, and
90th percentiles. Additionally, we also created standard
multivariate linear regression models with a quadratic term
to provide effect estimates for eGFRcr. Moreover, we adjusted
the associations of eGFRcr with arterial calciﬁcation for age
(represented as spline) and interactions of age (as a spline)
and sex. Since nonlinear associations with eGFRcr could be
reﬂective of non-GFR determinants, such as loss of muscle
mass, we used eGFRcys for later analyses. We further
compared the incidence rates of cardiovascular disease per
1000 person-years in different categories of kidney function
(based on eGFRcys) and arterial calciﬁcation.14 We used the
globally accepted cutoff of 60 mL/min per 1.73 m2 for eGFR
to deﬁne CKD.15,16 Next, the categories were deﬁned as (1)
eGFRcys >60 mL/min per 1.73 m2 and no calciﬁcation, (2)
presence of either eGFRcys <60 mL/min per 1.73 m2 or
calciﬁcation, and (3) eGFRcys <60 mL/min per 1.73 m2 and
presence of calciﬁcation. For this analysis, we excluded those
with previous history of cardiovascular disease (sample
size=2091). We conducted a mediation analysis using the
approach developed by Valeri and Van der Weele.17,18 We
presented total effect as well as natural direct effect
(exposure effect that is not mediated by the mediator) and
natural indirect effect (exposure effect that is mediated by the
mediator). To explore the presence of interaction between
worse kidney function and arterial calciﬁcation, we also
evaluated all models after including an interaction term
between kidney measures and volumes of arterial
calciﬁcation.
Results
Table 1 presents the characteristics of the study participants
at the time of kidney function measurement. Mean age of the
population was 69.56.7 years and 52% were female. Eighty
percent of the population had an eGFRcys that was >60 mL/
min per 1.73 m2; in 10% this was between 45 and 60 mL/min
per 1.73 m2, and in 2% the eGFRcys was <45 mL/min per
1.73 m2. The associations between markers of kidney
function and calciﬁcation in different vascular beds are
presented in Table 2. In the age- and sex-adjusted models,
lower eGFRcys was associated with larger volumes of aortic
arch calciﬁcation (difference in Ln-transformed calciﬁcation
Table 1. Baseline Characteristics of Study Participants
Sample size, n 2241
Age, y 69.5 (6.7)
Women 1163 (51.9)
Systolic blood pressure, mm Hg 141.7 (20.8)
Diastolic blood pressure, mm Hg 78.3 (10.8)
Body mass index, kg/m2 26.9 (3.7)
Current smoking 402 (18.0)
Total cholesterol, mmol/L 5.8 (0.9)
HDL cholesterol, mmol/L 1.4 (0.4)
Hypertension 1334 (59.5)
Diabetes mellitus 214 (9.5)
eGFR creatinine, mL/min per 1.73 m2 79.3 (13.8)
eGFR cystatin C, mL/min per 1.73 m2 80.2 (17.0)
Albumin-to-creatinine ratio, mg/g 4.5 (2.4–10.4)
Coronary artery calcification, mm3 52.1 (1.8–271.4)
Aortic arch calcification, mm3 250.7 (42.8–827.2)
Extracranial carotid artery calcification, mm3 22.5 (0–113.6)
Intracranial carotid artery calcification, mm3 42.3 (6.7–140.5)
Categorical variables are presented as numbers (percentages), continuous variables as
means (SD), and albumin-to-creatinine ratio and calciﬁcation markers are presented as
medians (interquartile ranges). The following variables had missing data: body mass
index (n=7), systolic and diastolic blood pressure (n=5), hypertension (n=12), smoking
(n=9), and history of diabetes mellitus (n=9). eGFR indicates estimated glomerular
ﬁltration rate; HDL, high-density lipoprotein.
Table 2. Association Between Kidney Function and Calciﬁcation in Major Arteries
CAC AAC ECAC ICAC
Difference (95% CI)* P Value
eGFRcys (n=2195)*
Model 1 0.04 (0.01, 0.08) 0.086 0.07 (0.02, 0.12) 0.003 0.05 (0.01, 0.09) 0.040 0.06 (0.02, 0.11) 0.009
Model 2 0.01 (0.03, 0.05) 0.663 0.04 (0.00, 0.09) 0.062 0.03 (0.02, 0.08) 0.195 0.04 (0.01, 0.09) 0.078
ACR (n=1767)*
Model 1 0.06 (0.04, 0.09) 0.001 0.05 (0.02, 0.08) 0.001 0.04 (0.01, 0.07) 0.012 0.05 (0.02, 0.07) 0.002
Model 2 0.04 (0.01, 0.07) 0.004 0.03 (0.01, 0.06) 0.042 0.02 (0.01, 0.05) 0.214 0.03 (0.00, 0.06) 0.063
Model 1: Adjusted for age, sex, and cohort effect. Model 2: Adjusted for model 1 and additionally for body mass index, hypertension, diabetes mellitus, smoking, total cholesterol, and HDL
cholesterol. AAC indicates aortic arch calciﬁcation; ACR, albumin-to-creatinine ratio; CAC, coronary artery calciﬁcation; ECAC, extracranial carotid artery calciﬁcation; eGFR, estimated
glomerular ﬁltration rate; eGFRcys, eGFR calculated for creatinine; HDL, high-density lipoprotein; ICAC, intracranial carotid artery calciﬁcation.
*Reported beta and CIs are standardized log increase in calciﬁcation per 1 SD decrease in eGFR estimates or doubling in ACR.
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volume per 1 SD lower eGFRcys: 0.07, 95% CI: 0.02, 0.12),
extracranial carotid artery calciﬁcation (difference: 0.05, 95%
CI: 0.01, 0.09), and intracranial carotid artery calciﬁcation
(difference: 0.06, 95% CI: 0.02, 0.11). A higher albumin-to-
creatinine ratio was associated with larger volumes of
coronary artery calciﬁcation (difference in Ln-transformed
calciﬁcation volume per doubling of albumin-to-creatinine
ratio: 0.06, 95% CI: 0.04, 0.09), aortic arch calciﬁcation
(difference: 0.05, 95% CI: 0.02, 0.08), extracranial carotid
artery calciﬁcation (difference: 0.04, 95% CI: 0.01, 0.07), and
intracranial carotid artery calciﬁcation (difference: 0.05, 95%
CI: 0.02, 0.07). After adjustment for cardiovascular risk
factors, the effect estimates attenuated and were no longer
statistically signiﬁcant for eGFR. The association between
Figure 2. Nonlinear association of eGFR based on creatinine and arterial calciﬁcation in different vascular
beds. X-axes represent eGFR values based on creatinine and Y-axes represent logarithm of arterial
calciﬁcation values. AAC indicates aortic arch calciﬁcation; CAC, coronary artery calciﬁcation; ECAC,
extracranial carotid artery calciﬁcation; eGFR, estimated glomerular ﬁltration rate; ICAC, intracranial carotid
artery calciﬁcation.
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albumin–creatinine ratio and calciﬁcation in coronary artery
calciﬁcation and aortic arch calciﬁcation remained statistically
signiﬁcant (Table 2). We noted a U-shaped association
between eGFRcr and calciﬁcation in all 4 vascular beds (all
P<0.05) (Figure 2 and Figure S1; results from standard linear
regression models including the quadratic term are shown in
Table S1). Figure S2 compares the model including eGFRcr as
nonlinear term and the model using both eGFRcr and
covariables as spline.
Participants with both eGFRcys <60 mL/min per 1.73 m2
and calciﬁcation in their vascular beds had higher incidence of
cardiovascular disease compared with individuals with
eGFRcys >60 and without calciﬁcation (all P<0.05) (Figure 3).
Table 3 presents the results of the mediation analysis.
Adjusted for age, sex, and cardiovascular risk factors, percent
mediated via arterial calciﬁcation in the observed association
between kidney function measures and incident cardiovascu-
lar disease was small and not statistically signiﬁcant (from 0%
to 23%). Including an interaction term between kidney
measures and volumes of arterial calciﬁcation did not
statistically signiﬁcantly improve the models (data not shown).
Discussion
In this population-based study, we found that a lower eGFRcys
and a higher albumin-to-creatinine ratio were associated with
higher volumes of calciﬁcation in the coronary arteries, the
aortic arch, and the extra- and intracranial internal carotid
arteries. The order of magnitude of these associations was
similar across all 4 vessels. The effect estimates attenuated
after adjustment for cardiovascular risk factors. We observed
a nonlinear association between eGFRcr and calciﬁcations in
all vessel beds. Adjusting for age, sex, and cardiovascular risk
factors, arterial calciﬁcation did not mediate the association
between kidney function and cardiovascular events.
Previous studies including kidney disease patients inves-
tigated the link between kidney function and calciﬁcation in
the coronary arteries and the aorta.19–25 Kidney impairment
has been associated with coronary calciﬁcation in different
populations.19,21,23,25 Reports on patients with chronic kidney
disease found an independent association between kidney
function and vascular calciﬁcation,19,21 whereas the associ-
ation was not independent of traditional cardiovascular risk
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Figure 3. Incidence rates of cardiovascular disorders in 3 categories of participants based on eGFR level
and presence of calciﬁcation. AAC indicates aortic arch calciﬁcation; CAC, coronary artery calciﬁcation;
CVD, cardiovascular disease; ECAC, extracranial carotid artery calciﬁcation; eGFR, estimated glomerular
ﬁltration rate; ICAC, intracranial carotid artery calciﬁcation.
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factors in the general population.23 Similarly, among predial-
ysis patients, lower eGFR was found to be prominently related
to the presence of abdominal aortic calciﬁcation.20 In
contrast, a report from the population-based Multi-Ethnic
Study of Atherosclerosis showed that mild impairment in
kidney function is only modestly associated with aortic valve
calciﬁcation.24 We observed that, similar to other population-
based studies, the effect estimates attenuated after adjust-
ment for cardiovascular risk factors, suggesting that in the
general population at least part of this association is
explained by cardiovascular risk factors. Vascular calciﬁcation
can be the consequence of a wide range of different biological
processes. In patients with more severe stages of kidney
disease, mechanisms directly related to lower glomerular
ﬁltration, such as disturbed calcium–phosphate metabolism,
or medical therapies to treat renal osteodystrophy, have also
been implicated in the pathophysiology of vascular calciﬁca-
tion.2,3,26 This could explain the association between kidney
function markers and calciﬁcation independent of cardiovas-
cular risk factors in a population with more advanced stages
of kidney impairment. Future studies investigating this
association in populations with lower levels of eGFR are
needed to explore mechanisms beyond cardiovascular risk
factors.
The present study extends the literature by including
calciﬁcation in vessels other than the coronary arteries or the
aorta. Calciﬁcation can have different anatomical and histo-
logical locations. Given that correlations between calciﬁca-
tions in different vessel beds are only moderate27,28 (r from
our study=0.4–0.5), the association between kidney function
and calciﬁcation could differ across various vessel beds with
potential implications for clinical events. For example, calci-
ﬁcation in intra- and extracranial arteries has been shown be a
strong predictor of stroke.5,7 Patients with kidney impairment
also have excess risk for stroke and one of the proposed
mechanisms is a higher load of arterial calciﬁcation in these
patients.29 Similar to coronary and aortic calciﬁcation, we
observed a trend showing an association between eGFR and
albuminuria with calciﬁcation in intracranial carotid arteries.
The strength of the association as well as the incidence rate
of cardiovascular disorders were similar across different
vessels, suggesting that the association between kidney
function and arterial calciﬁcation is not restricted to a
particular type of a vessel or region but rather a more
systemic phenomenon. We found that, in adjusted models, a
small portion of the association between kidney measures
and cardiovascular events was mediated through arterial
calciﬁcation and were not statistically signiﬁcant. Our popu-
lation-based cohort is relatively healthy with lower burden of
calciﬁcation, and the mediating role of calciﬁcation is likely
more prominent in patients with advanced chronic kidney
disease.
We noted a nonlinear association between creatinine-
based eGFR and calciﬁcation. Nonlinear associations of
creatinine in relation to cardiovascular outcomes have been
reported previously.12,30 Individuals with very low creatinine
levels (high eGFR) are also at increased risk of cardiovascular
disorders, possibly because of malnutrition and loss of muscle
Table 3. Estimates of Direct and Indirect Effects of Kidney Function Measures on Cardiovascular Disease and Percentage
Mediated by Arterial Calciﬁcation
Cardiovascular Disease
Percent Mediated*Natural Direct Effect Natural Indirect Effect Total Effect
Odds Ratio (95% CI) %
eGFR (per 1 SD decrease)
CAC 1.19 (0.98, 1.44) 1.00 (0.98, 1.03) 1.20 (0.99, 1.45) 0
AAC 1.17 (0.97, 1.42) 1.01 (0.99, 1.03) 1.19 (0.99, 1.44) 6
ECAC 1.17 (0.97, 1.42) 1.01 (0.99, 1.03) 1.18 (0.98, 1.43) 6
ICAC 1.18 (0.97, 1.42) 1.02 (0.99, 1.04) 1.19 (0.99, 1.44) 11
ACR (per doubling)
CAC 1.07 (0.95, 1.21) 1.02 (1.00, 1.03) 1.09 (0.96, 1.23) 23
AAC 1.07 (0.95, 1.21) 1.01 (0.99, 1.02) 1.08 (0.96, 1.22) 13
ECAC 1.08 (0.96, 1.22) 1.00 (0.99, 1.01) 1.08 (0.96, 1.22) 0
ICAC 1.08 (0.95, 1.21) 1.01 (0.99, 1.03) 1.09 (0.97, 1.23) 12
Models are adjusted for age, sex, cohort effect and body mass index, hypertension, diabetes mellitus, smoking, total cholesterol, and HDL cholesterol. AAC indicates aortic arch
calciﬁcation; ACR, albumin-to-creatinine ratio; CAC, coronary artery calciﬁcation; ECAC, extracranial carotid artery calciﬁcation; eGFR, estimated glomerular ﬁltration rate; HDL, high-
density lipoprotein; ICAC, intracranial carotid artery calciﬁcation.
*The portion of the total effects mediated by arterial calciﬁcation is deﬁned as the natural indirect effect over the total effect.
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mass.31 Unlike creatinine, levels of serum cystatin C are
reported to be independent of muscle mass.31 Nevertheless,
inﬂammation and cardiovascular risk factors such as obesity
and diabetes mellitus can also inﬂuence serum cystatin C
levels.31,32 Another reason for the nonlinear association of
eGFRcr and calciﬁcation could be because of the glomerular
hyperﬁltration. Hyperﬁltration has been associated with
vascular dysfunction because it may represent an adaptive
mechanism to maintain glomerular perfusion.33,34 Given that
the same trend was not observed with eGFR based on
cystatin C, this observation should be conﬁrmed in future
studies. We found more prominent associations when using
albuminuria as a marker of kidney function than when using
eGFR. This ﬁnding has been reported in different studies, with
albuminuria being a marker of generalized endothelial
dysfunction as the most appealing explanation.35,36 In
addition, albuminuria may better capture the inﬂuence of
other calcifying mechanisms such as inﬂammation in the
arterial system.37
We included a relatively large sample of community-
dwelling individuals with available standardized image-based
measures of calciﬁcation in 4 major vascular beds, and
different markers of kidney function that enabled 1-on-1
comparisons of kidney function measures and arterial calci-
ﬁcation in different vessel beds within this population.
However, limitations of our study should be acknowledged.
Given the relatively preserved eGFR in our population, the
ﬁndings are difﬁcult to extrapolate to older individuals and
people with more severe kidney disease. One of the main
assumptions of mediation analysis is to rule out confounding;
we adjusted the analyses for main cardiovascular risk factors
and demographic characteristics but there is the possibility of
residual confounding and reverse causation. One important
potential confounder that we did not take into account is the
level of serum phosphate. Serum phosphate has been found
to be an independent risk factor for cardiovascular events in
both the general population and in patients with kidney
disease. Future studies are needed to study the role of
phosphate in this association. Another important limitation of
this study is the time interval between measuring kidney
function and CT scan. Although adjustment for the time
interval did not change the results, we acknowledge that
during this interval there may have been changes in kidney
function measures.
In conclusion, we found that in the general population,
impairment of kidney function, particularly albumin-to-creati-
nine ratio, is associated with larger volumes of arterial
calciﬁcation in different major vascular beds. At least part of
this association is explained by cardiovascular risk factors.
The effect estimates did not seem to be more prominent with
1 vessel bed and was rather similar across all 4 vessels.
Arterial calciﬁcation did not mediate the association between
kidney function and cardiovascular disease above cardiovas-
cular risk factors in the general population.
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Table S1. The association between GFRcr/GFRcr squared and calcification in different arteries. 
 Difference (95% confidence interval)* 
 CAC AAC ECAC ICAC 
     
Model I (n=2241)     
GFRcr 0.34 (0.03, 0.65) 0.47 (0.15, 0.78) 0.78 (0.46, 1.11) 0.44 (0.12, 0.76) 
GFRcr^2 -0.37 (-0.69, -0.06) -0.51 (-0.83, -0.20)  -0.80 (-1.12, -0.48) -0.47 (-0.79, -0.14) 
     
Model II (n=2220)     
GFRcr 0.63 (-0.12, 1.38) 0.82 (0.12, 1.53) 1.55 (0.84, 2.25) 0.74 (0.09, 1.39) 
GFRcr^2 -0.70 (-1.45, 0.05) -0.91 (-1.62, -0.21)  -1.56 (-2.27, -0.86) -0.79 (-1.44, -0.14) 
     
Model 1: Adjusted for age, sex and cohort effect. 
Model 2: Adjusted for model 1+ body mass index, hypertension, smoking, diabetes mellitus, total cholesterol, and HDL cholesterol. 
*Reported beta and confidence intervals are standardized log increase in calcification per one SD lower GFR estimates. 
GFRcr^2 refers to addition of a squared GFR variable in the model. 
SD: standard deviation; CAC: Coronary artery calcification; AAC: Aortic arch calcification; ECAC: Extracranial carotid artery calcification; 
ICAC: Intracranial carotid artery calcification
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Figure S1. Non-linear association of kidney measures and arterial calcification in different 
vascular beds.  
 
 
X-axes represent values of eGFR or logarithm of albumin-to-creatinine ratio and Y-axes 
represent logarithm of arterial calcification values. CAC: Coronary artery calcification; AAC:  
Aortic arch calcification; ECAC: Extracranial carotid artery calcification; ICAC: Intracranial 
carotid artery calcification. 
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Figure S2. Non-linear association of eGFRcr and arterial calcification in different vascular 
beds.  
 
X-axes represent values of eGFRcr and Y-axes represent logarithm of arterial calcification 
values. Blue represent model including eGFRcr as a nonlinear term.  
Red represent model including eGFRcr as a nonlinear term as well as age (as spline) and 
interactions of age (as a spline) and sex.  
ECAC ICAC 
CAC AAC 
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